Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 4/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 4/20 | 0.52 |
| ▸ | IL1B | P01584 | 3/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.52 |
| ▸ | GSPT1 | P15170 | 5/20 | 0.51 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68283 | 0.93 | CRBN (0.55) | CRBNCSNK1A1TNFIKZF1IL1B | |
| SCHEMBL70131 | 0.88 | TNF (0.54) | CRBNCSNK1A1TNFIKZF1IL1B | |
| SCHEMBL61093 | 0.85 | CRBN (0.60) | CRBNCSNK1A1TNFIKZF1IL1B | |
| SCHEMBL69525 | 0.84 | CRBN (0.57) | CRBNCSNK1A1IKZF1DDB1IKZF3 | |
| SCHEMBL62299 | 0.84 | CRBN (0.55) | CRBNCSNK1A1TNFIKZF1IL1B | |
| SCHEMBL60982 | 0.83 | CRBN (0.66) | CRBNCSNK1A1TNFIKZF1IL1B | |
| SCHEMBL62525 | 0.81 | TNF (0.56) | CRBNCSNK1A1TNFIKZF1IL1B | |
| Formic Acid SCHEMBL61216 | 0.81 | CRBN (0.64) | CRBNCSNK1A1TNFIKZF1IL1B | |
| SCHEMBL70129 | 0.81 | CRBN (0.59) | CRBNCSNK1A1TNFIKZF1IL1B | |
| SCHEMBL17420449 | 0.81 | CRBN (0.68) | CRBNCSNK1A1TNFIKZF1IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2985281-A2 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Celgene Corporation (US) | 2016-02-17 | — | — | EP | disclosed |